

Oryzon to present at upcoming international conferences

- ❖ **11th Clinical Trials on Alzheimer's Disease, CTAD-2018, Barcelona, Spain**
- ❖ **European Alzheimer's Disease Consortium meeting, Barcelona, Spain**
- ❖ **24th Annual International Partnering Conference BIO-Europe-2018, Copenhagen, Denmark**
- ❖ **Jefferies London Healthcare Conference, London, UK**
- ❖ **2018 Citi Global Healthcare Conference, New York, USA**

MADRID, SPAIN and CAMBRIDGE, MA, UNITED STATES, October 22, 2018 - Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) ("Oryzon"), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that Executive Directors of Oryzon will present at several international reputed conferences in October and November 2018.

Executive Directors and scientists of Oryzon will participate in the 11th Clinical Trials on Alzheimer's Disease ("CTAD") international conference, CTAD-2018, to be held in Barcelona, Spain, at the Congress Center on October 24-27, 2018. Dr. Roger Bullock, Oryzon's Chief Medical Officer, will present a written communication entitled "*Using transcription phenotypes to utilise basket trial methodology from oncology to create new targets in CNS disorders*" at the "Clinical Trials: Methodology" session. CTAD is the most important international conference on clinical research in Alzheimer's disease and gathers every year scientists and clinicians from all over the world.

Dr. Roger Bullock will also make an oral presentation entitled "*ETHERAL: the first study using an epigenetic treatment in AD*" at the European Alzheimer's Disease Consortium meeting that will take place in Barcelona, Spain, on October 23-24, 2018.

Oryzon's executives will hold business meetings with other companies in the pharmaceutical sector at the 24th Annual International Partnering Conference BIO-Europe 2018 to be held in Copenhagen, Denmark, on November 5-7, 2018. Oryzon will discuss the progress in its five ongoing Phase IIa clinical trials on Wednesday, November 7, 2018, at 11:45 CET during the CNS/Neurology track. BIO-Europe is an annual event specialized in partnering and licensing alliances in the pharmaceutical sector.

Dr. Carlos Buesa, CEO of Oryzon, has been invited to attend the Healthcare Conference organized by Jefferies Investment Bank which will be held in London, UK, on November 14-15, 2018, where he will hold meetings with industry stakeholders.

Dr. Carlos Buesa has also been invited to attend the 2018 Citi Global Healthcare Conference which will be held in New York, USA, on December 5 and 6, 2018, at the Lotte Hotel, where he will hold meetings with industry stakeholders.

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon's LSD1 program has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon is publicly traded on the Spanish Automated Quotation System (Continuous Market) that includes the Madrid, Barcelona, Bilbao and Valencia Stock Exchanges. Oryzon has offices in Spain and the United States. For more information, visit www.oryzon.com.

FORWARD-LOOKING STATEMENTS

This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates" and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzon's securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzon's securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.

US Contact:
The Trout Group
Thomas Hoffmann
+1 646 378 2932
thoffmann@troutgroup.com

Spain:
ATREVIA
Patricia Cobo
+34 91 564 07 25
pcobo@atrevia.com

Oryzon:
Emili Torrell
BD Director
+34 93 515 13 13
etorrell@oryzon.com